These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22827250)

  • 1. Update in pharmacological management of coronary no-reflow phenomenon.
    Salinas P; Jimenez-Valero S; Moreno R; Sanchez-Recalde A; Galeote G; Calvo L; Ruiz-Garcia J; Carrizo S; Trucco G; Lopez-Sendon J
    Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):256-64. PubMed ID: 22827250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological approach of no-reflow phenomenon related with percutaneous coronary interventions.
    Valero SJ; Moreno R; Reyes RM; Recalde AS; Galeote G; Calvo L; Villate A; Sendón JL
    Cardiovasc Hematol Agents Med Chem; 2008 Apr; 6(2):125-9. PubMed ID: 18473777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of 'no-reflow' complicating reperfusion therapy.
    Lee KW; Norell MS
    Acute Card Care; 2008; 10(1):5-14. PubMed ID: 18449813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.
    Jaffe R; Dick A; Strauss BH
    JACC Cardiovasc Interv; 2010 Jul; 3(7):695-704. PubMed ID: 20650430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary Nicorandil and the Prevention of the No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction.
    Qi Q; Niu J; Chen T; Yin H; Wang T; Jiang Z
    Med Sci Monit; 2018 May; 24():2767-2776. PubMed ID: 29726480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial no-reflow treatment.
    Muller O; Trana C; Eeckhout E
    Curr Vasc Pharmacol; 2013 Mar; 11(2):278-85. PubMed ID: 23506504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The no-reflow phenomenon in the coronary circulation.
    Kiernan TJ; Ruggiero NJ; Bernal JM; Don CW; Witzke C; Kiernan GD; Cubeddu RJ; Yan BP
    Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):181-92. PubMed ID: 19689256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No-reflow phenomenon: maintaining vascular integrity.
    Kloner RA
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):244-50. PubMed ID: 21821523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials.
    Wang L; Cheng Z; Gu Y; Peng D
    Biomed Res Int; 2015; 2015():382086. PubMed ID: 26504804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.
    Niu X; Zhang J; Bai M; Peng Y; Sun S; Zhang Z
    BMC Cardiovasc Disord; 2018 Jan; 18(1):3. PubMed ID: 29320987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary No-Reflow Phenomenon in Clinical Practice.
    Scarpone M; Cenko E; Manfrini O
    Curr Pharm Des; 2018; 24(25):2927-2933. PubMed ID: 29962336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention.
    Movahed MR; Butman SM
    Cardiovasc Revasc Med; 2008; 9(1):56-61. PubMed ID: 18206640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological management of no reflow during percutaneous coronary intervention.
    Porto I; Ashar V; Mitchell AR
    Curr Vasc Pharmacol; 2006 Apr; 4(2):95-100. PubMed ID: 16611152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
    Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
    Aung Naing K; Li L; Su Q; Wu T
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009503. PubMed ID: 23736949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.
    Fu Q; Lu W; Huang YJ; Wu Q; Wang LG; Wang HB; Jiang SZ; Wang YJ
    Cell Biochem Biophys; 2013; 67(3):911-4. PubMed ID: 23559273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracoronary injection of drugs to treat no--reflow phenomenon and microcirculatory dysfunction.
    Rognoni A; Lupi A; Cavallino C; Secco GG; Rosso R; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):84-8. PubMed ID: 22973862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus.
    Sharma S; Lardizabal JA; Singh S; Sandhu R; Bhambi BK
    Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):152-9. PubMed ID: 22559269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.
    Kunadian V; Zorkun C; Williams SP; Biller LH; Palmer AM; Ogando KJ; Lew ME; Nethala N; Gibson WJ; Marble SJ; Buros JL; Gibson CM
    J Thromb Thrombolysis; 2008 Dec; 26(3):234-42. PubMed ID: 18818881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of urapidil on heart function and ventricular systolic synchrony in acute myocardial infarction patients with no-reflow phenomenon after percutaneous coronary intervention].
    Chen JL; Fu XH; Jiang YF; Fan WZ; Gu XS; Liu JJ; Geng W
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2008 Apr; 20(4):197-9. PubMed ID: 18419949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.